PMID- 8569196
OWN - NLM
STAT- MEDLINE
DCOM- 19960304
LR  - 20210102
IS  - 0023-6837 (Print)
IS  - 0023-6837 (Linking)
VI  - 74
IP  - 1
DP  - 1996 Jan
TI  - Tumor infiltrating lymphocytes in lymph node melanoma metastases: a 
      histopathologic prognostic indicator and an expression of local immune response.
PG  - 43-7
AB  - In lymph node melanoma metastases, the expansive proliferation of tumor cells may 
      be compared, structurally and cytologically, to the vertical growth phase (VGP) 
      observed in primary melanoma. Both in VGP and in nodal metastases, tumor 
      infiltrating lymphocytes (TILs) may be present with different patterns. In the 
      evaluation of the primary tumor, these patterns have been defined as brisk, 
      non-brisk, and absent. The histologic slides of regional lymph node metastases, 
      the site of first recurrence in 99 consecutive melanoma patients, were reviewed. 
      Disease-free survival of these cases and whether or not they were treated with 
      rIFN alpha-2A was recorded to identify any relationship among different patterns 
      of TILs, therapy, and prognosis. Of 99 cases, 16 were classified as brisk, 37 as 
      non-brisk, and 46 as absent. At 30 months of follow-up the disease-free survival 
      was 81.3% for brisk cases, 46.8% for non-brisk cases, and 29.3% for absent groups 
      (p = .007). Multivariate analysis confirmed the prognostic value of TILs in 
      predicting disease-free survival in patients with regional node metastases. The 
      difference according to the presence or absence of relapse is particularly 
      evident when comparison is made between treated and untreated patients. In 
      conclusion the evaluation of first-recurrence regional node melanoma metastases 
      for TILs, using the same histopathologic criteria as in VGP of primary melanoma, 
      subdivides the cases in brisk, non-brisk, and absent groups. Also, the presence 
      of these patterns in metastatic node melanoma deposits is correlatable to 
      disease-free survival. Our results further stress the difference of prognosis 
      patients treated with rIFN alpha-2A compared to the untreated group. The TILs 
      evaluation may prove useful in selecting those melanoma stage II patients who 
      will best respond to therapy with biologic response modifiers, because the TILs 
      may be the local immune effector cell targets of rIFN alpha-2A or of other 
      biologic agents.
FAU - Mihm, M C Jr
AU  - Mihm MC Jr
AD  - Division of Dermatopathology, Albany Medical College, New York, USA.
FAU - Clemente, C G
AU  - Clemente CG
FAU - Cascinelli, N
AU  - Cascinelli N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Lab Invest
JT  - Laboratory investigation; a journal of technical methods and pathology
JID - 0376617
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Humans
MH  - Immunologic Factors/therapeutic use
MH  - Lymphatic Metastasis/*pathology
MH  - Lymphocytes, Tumor-Infiltrating/*pathology
MH  - Melanoma/*immunology/*pathology/therapy
MH  - Neoplasm Recurrence, Local/*pathology
MH  - Neoplasm Staging
EDAT- 1996/01/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
PST - ppublish
SO  - Lab Invest. 1996 Jan;74(1):43-7.